Tafamidis and newer transthyretin stabilizers have redefined the prognosis of transthyretin amyloidosis, myosin inhibitors represent a breakthrough in hypertrophic cardiomyopathy, and structured surveillance has been recognized as essential in Takotsubo syndrome. The gene discussed is TTR; the disease is hypertrophic cardiomyopathy.